ArticleNPJ precision oncology2026
Decoding spatial mTOR signalling reveals distinct roles in the tumour microenvironment.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The tumour microenvironment comprises a variety of cell types that interact with malignant cells, influencing both cancer progression and the patient response to therapy. Given the intricate interactions among these components, assessing how signalling pathways contribute to cancer progression by acting on different components of the TME is particularly complex. Multiplexed imaging allows simultaneous assessment of signalling in multiple of these components. Here, we utilise a highly multiplexed dataset of 61 markers across 746 colorectal tumours to investigate how complex mTOR signalling in different tissue compartments influences patient prognosis. We found that mTOR pathway signalling in immune cells correlates with favourable patient survival. Advanced spatially-aware analysis of signalling activities using graph neural networks revealed that the positive association between immune mTOR signalling and patient survival was more pronounced in tumours with features of a more differentiated morphology. Integrative analysis using TCGA data and spatial transcriptomics confirmed a role for immune mTOR signalling in immune activation, accompanied by reduced TGF-β signalling. Our work highlights the importance of adopting a personalised approach to targeting mTOR in cancer patients and establishes a framework for studying cell type-specific signalling in the TME.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.